These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 12945089)

  • 1. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients (Br J Surg 2003; 90: 547-548).
    Vincenzi B; Santini D; Avvisati G; Borzomati D; Tonini G
    Br J Surg; 2003 Sep; 90(9):1165-6. PubMed ID: 12945089
    [No Abstract]   [Full Text] [Related]  

  • 2. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients.
    Frederiksen SG; Hedenbro JL; Norgren L
    Br J Surg; 2003 May; 90(5):547-8. PubMed ID: 12734859
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials.
    Davidson BL; Büller HR; Decousus H; Gallus A; Gent M; Piovella F; Prins MH; Raskob GE; Segers AE; Lensing AW;
    J Thromb Haemost; 2007 Jun; 5(6):1191-4. PubMed ID: 17403087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
    Hammerstingl C; Omran H; Tripp C; Poetzsch B
    Thromb Haemost; 2009 Feb; 101(2):325-32. PubMed ID: 19190817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the biological activity of 2 formulations of enoxaparin in 12 healthy volunteers.
    Sharma V; Madhu S; Natarajan P; Muniyandi G; Jaiswal V; Saxena R
    Clin Appl Thromb Hemost; 2010 Aug; 16(4):387-93. PubMed ID: 19671565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative.
    Spinler SA; Ou FS; Roe MT; Gibler WB; Ohman EM; Pollack CV; Alexander KP; Peterson ED
    Pharmacotherapy; 2009 Jun; 29(6):631-8. PubMed ID: 19476416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different effects of enoxaparin and unfractionated heparin on some thrombogenesis markers during hemodialysis: a cross-over study.
    Naumnik B; Pawlak K; Myśliwiec M
    Thromb Res; 2009 Feb; 123(4):631-6. PubMed ID: 18234290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction.
    George-Phillips KL; Bungard TJ
    Pharmacotherapy; 2006 Oct; 26(10):1479-90. PubMed ID: 16999658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery.
    Van Thiel D; Kalodiki E; Wahi R; Litinas E; Haque W; Rao G
    Clin Appl Thromb Hemost; 2009; 15(4):389-94. PubMed ID: 19608550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A bioavailability study in the proposed patient population--with much more needed now.
    Freedman MD
    Crit Care Med; 2003 May; 31(5):1588-9. PubMed ID: 12771643
    [No Abstract]   [Full Text] [Related]  

  • 11. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
    Cheng S; Morrow DA; Sloan S; Antman EM; Sabatine MS
    Circulation; 2009 Mar; 119(9):1195-202. PubMed ID: 19237657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively.
    Pleym H; Videm V; Wahba A; Asberg A; Amundsen T; Bjella L; Dale O; Stenseth R
    Eur J Cardiothorac Surg; 2006 Jun; 29(6):933-40. PubMed ID: 16675258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
    Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once atrial fibrillation, always oral anticoagulation?
    Verheugt FW
    Thromb Res; 2007; 119(3):275-6. PubMed ID: 16426666
    [No Abstract]   [Full Text] [Related]  

  • 15. Is the preoperative administration of enoxaparin 40 mg necessary to optimally prevent the occurrence of venous thromboembolism after hip surgery? A subanalysis of two pooled randomized trials.
    Lassen MR
    J Thromb Haemost; 2009 May; 7(5):889-91. PubMed ID: 19245416
    [No Abstract]   [Full Text] [Related]  

  • 16. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
    Nutescu EA; Spinler SA; Wittkowsky A; Dager WE
    Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration.
    Cavusoglu E; Lakhani M; Marmur JD
    J Invasive Cardiol; 2005 Aug; 17(8):416-21. PubMed ID: 16079447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
    Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
    J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosage of enoxaparin among obese and renal impairment patients.
    Bazinet A; Almanric K; Brunet C; Turcotte I; Martineau J; Caron S; Blais N; Lalonde L
    Thromb Res; 2005; 116(1):41-50. PubMed ID: 15850607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity.
    Borkgren-Okonek MJ; Hart RW; Pantano JE; Rantis PC; Guske PJ; Kane JM; Gordon N; Sambol NC
    Surg Obes Relat Dis; 2008; 4(5):625-31. PubMed ID: 18261965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.